... (NCT03948867) is a prospective phase 2 open-label hydroxyurea trial for SCA in Tanzania. Methods: After formal training and certification, local personnel screened children 2–16 years old; those with conditional (170–199 cm/s) or abnormal (≥200 cm/s) time-averaged mean velocities (TAMVs) received hydroxyurea...

... , and MPL mutations, respectively. Of physician-assigned risk assessments, 41.8% were misclassifications based on data-derived risk assessment. Most patients (93.3%) received first-line hydroxyurea (HU) cytoreductive therapy. Discontinuations were primarily for intolerance (35.4%) and resistance (23.8...

... of the globin chains. Haemoglobin E (HbE)-β-thalassaemia is the genotype responsible for approximately one-half of all cases of severe β-thalassaemia worldwide. This study proposes to evaluate response of hydroxyurea in reducing transfusion requirements of severe HbE-β-thalassaemia patients, and its correlation...

... anemia (SCA) treated with hydroxyurea (HU) and 13 SCA patients without this treatment. MP concentrations were determined by flow cytometry. Coagulation was evaluated using the thrombin-antithrombin complex (TAT) and D-dimers. Total MP concentrations were increased in the HU-treated group (265 × 10 6 /ml...

...Zina Ben-Ishay; Sara Sharon; Fanny Reichert Donor rats of the Hebrew University strain were administered a single intraperitoneal injection of hydroxyurea (400 mg/kg body weight). 1–3 h following the administration of the drug, a suspension of spleen cells, the majority of which consisted...

...P. Kubisz; M. Pařizek; J. Kováčová; S. Cronberg Hydroxyurea added to citrated platelet-rich plasma in vitro did not influence the aggregation of the platelets, their adhesion to glass, their release of aggregating activity, platelet factor 4 or availability of platelet factor 3. Neither did it have...

.... 5 06 1979 23 08 1979 27 2 2009 Busulfan Chronic myeloid leukemia Cyclic oscillations in leucocyte count Hydroxyurea Acta haemat. 63: 68-70 (1980) Cyclic Oscillations in Leukocyte Count in Chronic Myeloid Leukemia B. C. Mehta and M. B. Agarwal Hematology Department, KEM...

...A. Abdul-Kareem; M. Al-Momen A 23-year-old man with severe sickle cell disease and a chronic non-healing left leg ulcer was entered into a study in which he received hydroxyurea (HU) and recombinant human erythropoietin (r-HuEPO) in order to modify the severity of his disease. HU 20 mg/kg/day...

... females, age range 20-47 years)], suffering from a severe form of the disease were enrolled in a treatment protocol using hydroxyurea (HU) for up to 12 months followed by a combination therapy with HU and human recombinant erythropoietin (rHuEpo; using 400 U/kg/week i.v.) for 3-4 weeks. Following...

...Mohsen Ali Fans El-Hazmi; Abdulkareem Al-Momen; Arjumand Sultan Warsy; S. Kandaswamy; Sameer Huraib; Mohamed Harakati; Fahd Al-Mohareb Hydroxyurea (HU) and recombinant human erythropoietin (rHuEpo) have been used in several studies to elevate Hb F level in sickle cell disease (SCD) patients...

...Mohsen A.F. El-Hazmi; Arjum S. Warsy; Abdulkarim Al-Momen; Mohamed Harakati In this study 21 adults with severe form of sickle cell disease (SCD; sickle cell anaemia, n = 15; Hb S/β°-thal, n = 6) were treated with hydroxyurea (HU) to assess the effectiveness of the drug in managing SCD...

.... Hydroxyurea (HU) is the best conventional drug for treatment of CML in the chronic phase. Ten patients, six men and four women, 40-70 years of age, were treated during the accelerated phase of CML with a combination of IFN and HU. Patients had received only HU during the chronic phase of the disease. All...

...Fuad Shammas; Peter Meyer; Reino Heikkila; Terje Apeland; Lasse Gøransson; Janicke Berland; Kjell Kjellevold We describe the case of a 57-year-old woman with chronic myelogenous leukemia who was on hydroxyurea and developed a fatal thrombotic microangiopathy with renal, retinal and central nervous...

... and to improve fetal outcome (data from 14 patients). After treatment with IFN-α, sufficient numbers of umbilical cord blood stem cells can be collected. Anagrelide Aspirin Blood collection Essential thrombocythemia Hydroxyurea Interferon alpha-2a Umbilical cord It is advisable to treat...

...Andrei Braester; Miriam Quitt We report on a patient with essential thrombocythemia treated with hydroxyurea who became febrile 3 weeks after the treatment was started. After drug withdrawal, the fever resolved but after rechallenge there was recurrence of the fever. Although hydroxyurea-induced...

...A.W. Saleh; H.F.P. Hillen; A.J. Duits It has been shown that the clinical course of sickle cell (SS) patients can be ameliorated by administration of hydroxyurea (HU). Induction of hemoglobin F (HbF) is thought to be the mechanism responsible for clinical improvement in some patients. However, HU...

...A.W. Saleh; A.J. Duits; A. Gerbers; C. de Vries; H.F.P. Hillen Hydroxyurea (HU) induces HbF production and can reduce painful crises in some patients with sickle cell anemia (SS). However, HbF induction alone cannot explain the beneficial effect of HU treatment as some patients experience clinical...